SCHEMBL769636

SCHEMBL769636

COc1ccc(-n2cnc3cc(NCc4ccc(OCCc5ccccc5)cc4)ccc32)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.65
KDM4E B2RXH2 10/20 0.65
ALDH1A1 P00352 10/20 0.65
HPGD P15428 8/20 0.65
GAA P10253 5/20 0.65
TDP1 Q9NUW8 4/20 0.65
L3MBTL1 Q9Y468 3/20 0.65
KIT P10721 2/20 0.63
FLT3 P36888 2/20 0.63
NPC1 O15118 7/20 0.61
RAB9A P51151 7/20 0.61
SMN1; SMN2 Q16637 5/20 0.61
LMNA P02545 4/20 0.61
ALOX15 P16050 1/20 0.61
TSHR P16473 1/20 0.61
HTT P42858 2/20 0.59
MEN1 O00255 1/20 0.59
MAPK1 P28482 1/20 0.59
KMT2A Q03164 1/20 0.59
NPSR1 Q6W5P4 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL769148 0.94 MAPT (0.70) MAPTKDM4EALDH1A1HPGDGAA
SCHEMBL770202 0.90 MAPT (0.67) MAPTKDM4EALDH1A1HPGDGAA
SCHEMBL769285 0.90 MAPT (0.70) MAPTKDM4EALDH1A1HPGDGAA
SCHEMBL769090 0.90 KIT (0.77) MAPTKDM4EALDH1A1HPGDGAA
SCHEMBL769327 0.90 RAB9A (0.57) MAPTKDM4EALDH1A1HPGDGAA
SCHEMBL770038 0.89 MAPT (0.72) MAPTKDM4EALDH1A1HPGDGAA
SCHEMBL769341 0.88 MAPT (0.70) MAPTKDM4EALDH1A1HPGDGAA
SCHEMBL770130 0.88 MAPT (0.70) MAPTKDM4EALDH1A1HPGDGAA
SCHEMBL769578 0.88 MAPT (0.65) MAPTKDM4EALDH1A1HPGDGAA
SCHEMBL769809 0.88 MAPT (0.65) MAPTKDM4EALDH1A1HPGDGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8871746-B2 Antiviral drugs for treatment of arenavirus infection Kineta Four, LLC (US) 2014-10-28 US claimed
US-20120071447-A1 Antiviral Drugs for Treatment of Arenavirus Infection SIGA TECHNOLOGIES INC. (US) 2012-03-22 US claimed
US-8871746-B2 Antiviral drugs for treatment of arenavirus infection Kineta Four, LLC (US) 2014-10-28 US disclosed
US-8871746-B2 Antiviral drugs for treatment of arenavirus infection Kineta Four, LLC (US) 2014-10-28 US disclosed
US-8871746-B2 Antiviral drugs for treatment of arenavirus infection Kineta Four, LLC (US) 2014-10-28 US disclosed
US-20120071447-A1 Antiviral Drugs for Treatment of Arenavirus Infection SIGA TECHNOLOGIES INC. (US) 2012-03-22 US disclosed
US-20120071447-A1 Antiviral Drugs for Treatment of Arenavirus Infection SIGA TECHNOLOGIES INC. (US) 2012-03-22 US disclosed
US-20120071447-A1 Antiviral Drugs for Treatment of Arenavirus Infection SIGA TECHNOLOGIES INC. (US) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071447-A1 Antiviral Drugs for Treatment of Arenavirus Infection ZC3HAV1, GZMB, GTF3C3 MAPT 2844/4885KDM4E 1661/4885ALDH1A1 4456/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.